Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AMARANTH

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

- PMLiVE

Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine

Early-stage trial will enrol 30 healthy volunteers aged 18-40

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

- PMLiVE

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

Specific review of thrombotic events found no increased risk of thrombosis associated with vaccine

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

- PMLiVE

EMA review confirms AZ/Oxford’s COVID-19 vaccine is safe and effective

EU regulator said that the vaccine is not associated with an increase in the overall risk of blood clots

- PMLiVE

Lilly reports positive data from its phase 3 ulcerative colitis trial

IL-23 blocker mirikizumab helped patients achieve clinical remission in 12-week induction study

- PMLiVE

Benefits of AZ COVID-19 vaccine ‘continue’ to outweigh risks, says EMA’s executive director

EU regulator is expected to publish findings from its investigation on Thursday

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links